STX 100

Drug Profile

STX 100

Alternative Names: BG-00011; STX-100

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Antifibrotics; Monoclonal antibodies
  • Mechanism of Action Integrin alphaVbeta6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrosis; Idiopathic pulmonary fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis

Most Recent Events

  • 23 Jul 2015 STX 100 is still in phase II trials for Idiopathic pulmonary fibrosis in USA
  • 30 Jun 2012 Phase-II clinical trials in Idiopathic pulmonary fibrosis in USA (SC)
  • 01 Sep 2010 STX 100 receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top